ADAMTS13 and Fabry disease: Similar to ADAMTS-13 results, the mean plasmatic concentration of GDF-15 (Figure 7) was higher in FD patients compared to controls, although the differences were not significant among the groups (1.95 ± 0.38 ng/mL in controls and 2.90 ± 0.48 ng/mL in FD patients: in naïve 2.46 ± 0.56 ng/mL and in ERT-treated 3.19 ± 0.61 ng/mL).